Get the Stockscreener App
96.06
2.45%
-2.41
After Hours:
95.67
-0.39
-0.41%
Rhythm Pharmaceuticals Inc stock is traded at $96.06, with a volume of 1.15M.
It is down -2.45% in the last 24 hours and down -8.42% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$98.47
Open:
$99.4
24h Volume:
1.15M
Relative Volume:
1.53
Market Cap:
$6.41B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-34.19
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-7.52%
1M Performance:
-8.42%
6M Performance:
-0.41%
1Y Performance:
+66.66%
1-Day Range:
$95.66
$101.61
1-Week Range:
$95.66
$109.51
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
96.06 | 6.57B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity - TipRanks
What is the earnings history of Rhythm Pharmaceuticals Inc2025 EndofYear Setup & Accurate Intraday Trade Tips - baoquankhu1.vn
Earnings Miss: Can Rhythm Pharmaceuticals Inc expand into new marketsStock Surge & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Rhythm Pharmaceuticals at Guggenheim Summit: Expanding Horizons in Biotech By Investing.com - Investing.com Canada
Earnings Risk: Is Rhythm Pharmaceuticals Inc currently under institutional pressure2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews - MSN
Candriam S.C.A. Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Bond Watch: Will Rhythm Pharmaceuticals Inc benefit from green energy policies2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com - Investing.com Canada
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock - MarketBeat
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals' CFO Hunter C. Smith to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - ChartMill
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by New York State Common Retirement Fund - MarketBeat
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
WCM Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
This High-Flying Growth Stock Is Hiding in Plain Sight - Finviz
Federated Hermes Inc. Has $174.50 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
EFG Asset Management North America Corp. Invests $2.05 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Bank Watch: Will Rhythm Pharmaceuticals Inc stock go up in YEARMarket Weekly Review & Daily Price Action Insights - baoquankhu1.vn
Aug Breakouts: What hedge funds are buying Rhythm Pharmaceuticals IncWall Street Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 37.5% Potential Upside in Biotech - DirectorsTalk Interviews
Aug Technicals: Is INVO Fertility Inc stock heavily shortedJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
(RYTM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
What is HC Wainwright's Estimate for RYTM FY2025 Earnings? - MarketBeat
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Zacks Research Downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Strong Sell - MarketBeat
Earnings Miss: Will Rhythm Pharmaceuticals Inc stock go up in YEARTake Profit & Weekly Return Optimization Alerts - baoquankhu1.vn
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - MSN
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright - Investing.com Canada
Breaking Down Rhythm Pharmaceuticals: 13 Analysts Share Their Views - Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for RYTM with Increased Price Target | RYTM Stock News - GuruFocus
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025 - Sahm
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Responsive Playbooks and the RYTM Inflection - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 38% Potential Upside - DirectorsTalk Interviews
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders - Sahm
Rhythm Pharmaceuticals stock price target raised to $130 from $120 at TD Cowen - Investing.com Canada
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $148 | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projects Strong Revenue Growth for 2025 - GuruFocus
Rhythm Pharmaceuticals announces preliminary, unaudited fourth quarter results - marketscreener.com
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - The Manila Times
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - Улправда
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Hunter C | Chief Financial Officer |
Feb 04 '26 |
Sale |
105.99 |
3,247 |
344,145 |
128,918 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):